The pivotal role of IFN-I in SLE pathogenesis led to the development of anifrolumab (SaphneloTM), a human IgG1κ monoclonal antibody that antagonizes the type 1 interferon receptor subunit 1 (IFNAR1) to inhibit IFN-I signaling, involved in innate and adaptive antiviral immunity across various cells [2,30]. This evidence concerns the gene IFNAR1 and systemic lupus erythematosus.